Abstract Number: 1485 • 2014 ACR/ARHP Annual Meeting
Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study
Background/Purpose Active RA significantly impairs health-related quality of life (HRQoL) and physical function of patients. Granulocyte-macrophage colony-stimulating factor (GM-CSF) plays a key role in macrophage…Abstract Number: 1484 • 2014 ACR/ARHP Annual Meeting
Discovery of ARN-4079 – a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis
Background/Purpose: The Non-receptor tyrosine kinases, JAK3 and ITK are key regulators of cytokine pathways and are important clinically validated targets, which offer the potential for…Abstract Number: 1483 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Baricitinib in Japanese Rheumatoid Arthritis Patients during a 52 Week Extension Phase
Background/Purpose Baricitinib (bari), an oral JAK1/JAK2 signaling inhibitor, was evaluated in a blinded phase 2b study for 12 weeks as a treatment for rheumatoid arthritis…Abstract Number: 1502 • 2014 ACR/ARHP Annual Meeting
A Phase I Trial Comparing PF-05280586 (A Potential Biosimilar) and Rituximab in Subjects with Active Rheumatoid Arthritis
Background/Purpose: PF-05280586, a proposed biosimilar to rituximab, has the same primary amino acid sequence as rituximab with similar physicochemical and in vitro functional properties. This…Abstract Number: 1501 • 2014 ACR/ARHP Annual Meeting
Immunogenicity Assessment of PF-06438179, a Potential Biosimilar to Infliximab, in Healthy Volunteers
Background/Purpose: PF-06438179, a proposed biosimilar to infliximab, was evaluated for immunogenicity in a phase 1 pharmacokinetic (PK) similarity study. Methods: In this double-blind trial (NCT01844804),…Abstract Number: 1500 • 2014 ACR/ARHP Annual Meeting
Preclinical and Clinical Characterization of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, in Normotensive and Hypertensive Cardiovascular Models
Background/Purpose: Spleen Tyrosine Kinase (SYK) and Zeta-chain-associated protein kinase 70 (ZAP70) are non-receptor protein kinases that bind phosophorylated receptor tyrosine-based activation motifs, critical in immune…Abstract Number: 1499 • 2014 ACR/ARHP Annual Meeting
Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor
Background/Purpose Jak kinase blockade can effectively manage rheumatoid arthritis (RA) and in some cases achieve remission. However, first generation Jak inhibitors have not met expectations…Abstract Number: 1498 • 2014 ACR/ARHP Annual Meeting
ALX-0061, an Anti-IL-6R Nanobody® for use in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab
Background/Purpose Interleukin-6 (IL-6) is a pleiotropic cytokine inducing a wide range of biological activities via its receptor, which can either be soluble (sIL-6R) or membrane-bound…Abstract Number: 1497 • 2014 ACR/ARHP Annual Meeting
Efficacy and Safety of Iguratimod for Rheumatoid Arthritis
Background/Purpose: Iguratimod is a new small-molecular drug for rheumatoid arthritis (RA), which was approved on June, 2012 in Japan. The agent inhibits the production of…Abstract Number: 1496 • 2014 ACR/ARHP Annual Meeting
Exposure-Response Analysis for Mavrilimumab Phase2b Study in RA Patients with Informative Dropout
Background/Purpose: Mavrilimumab is a recombinant human monoclonal antibody which neutralizes granulocyte-macrophage colony stimulating factor (GM-CSF) activity by selectively binding to the alpha subunit of its…Abstract Number: 1495 • 2014 ACR/ARHP Annual Meeting
Preclinical and Clinical Phase I Profile of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, Developed for the Treatment of Rheumatoid Arthritis
Background/Purpose: Spleen tyrosine kinase (SYK) is a potential target for treatment of several diseases including rheumatoid arthritis. SYK is a member of the Zeta-chain-associated protein…Abstract Number: 1494 • 2014 ACR/ARHP Annual Meeting
Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis-Specific Blood Gene Signature to Healthy State
Background/Purpose The 4 Janus kinases (JAK1, JAK2, JAK3 and TYK2) are cytoplasmic tyrosine kinases that mediate intracellular signaling of cytokines (e.g. certain interleukins and interferons)…Abstract Number: 1493 • 2014 ACR/ARHP Annual Meeting
A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results
Background/Purpose Activation of CSF1R via IL34 or CSF1 results in activation, differentiation, and survival of monocytes, macrophages and osteoclasts. CSF1R activation produces inflammatory cytokines responsible…Abstract Number: 1491 • 2014 ACR/ARHP Annual Meeting
Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases
Background/Purpose: Biologics such as TNF inhibitors have revolutionized the treatment of inflammatory diseases including rheumatoid arthritis (RA), psoriasis and psoriatic arthritis. However, recent data suggest that…Abstract Number: 1490 • 2014 ACR/ARHP Annual Meeting
Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers
Background/Purpose Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by joint and bone destruction. Loss of bone in RA is not only localized in…
ACR Meeting Abstracts